Last 67.00
Change Today +1.20 / 1.82%
Volume 187.3K
BLRX On Other Exchanges
Tel Aviv
As of 4:03 AM 12/25/14 All times are local (Market data is delayed by at least 15 minutes).

biolinerx ltd (BLRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/8/14 - $111.00
52 Week Low
12/3/14 - $46.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOLINERX LTD (BLRX)

biolinerx ltd (BLRX) Related Businessweek News

No Related Businessweek News Found

biolinerx ltd (BLRX) Details

BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; and BL-9020 for the treatment of type 1 diabetes. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

43 Employees
Last Reported Date: 03/17/14
Founded in 2003

biolinerx ltd (BLRX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biolinerx ltd (BLRX) Key Developments

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference

BioLineRx Ltd. announced that data from the on-going Phase 2a clinical trial of BL-8040 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) were reported at the American Society of Hematology (ASH) meeting, held on December 6-9, 2014, in San Francisco. Results reported to date in the dose-escalation stage of the Phase 2a study show that, even at the high dose reached to date (1.25 mg/kg), there were no dose-limiting toxicity events or serious adverse events, nor early discontinuations attributable to BL-8040. Furthermore, BL-8040 triggered substantial mobilization of AML cancer cells from the bone marrow to the peripheral blood, with a median 6-fold increase of AML cells in the blood. This mobilization is crucial for exposing a higher ratio of AML cells to accompanying chemotherapy such as Ara-C. Additional results show that after only two days of BL-8040 monotherapy, there was a median decrease of approximately 70% in the amount of AML cells in the bone marrow, while the levels of normal progenitor cells remained stable. Furthermore, BL-8040 as a monotherapy showed a 3.5-fold increase in cell death (apoptosis) of AML cells, both in the bone marrow and in peripheral blood samples. The dose escalation stage, which is currently ongoing, is expected to be completed early next year. The full study is expected to be completed in the second half of 2015.

BioLineRx, Ltd. - Shareholder/Analyst Call

To present the company's 2015 clinical development strategy for BL-8040 (AML and other hematological indications)

BioLineRx, Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

BioLineRx, Ltd. Reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating loss of ILS 14.289 million compared to ILS 11.584 million a year ago. Financial income was ILS 8.069 million compared to ILS 0.501 million a year ago. Comprehensive loss for the period was ILS 2.507 million compared to ILS 17.666 million a year ago. Basic and diluted loss per share were ILS 0.008 compared to ILS 0.077 a year ago. For the nine months, the company reported operating loss of ILS 42.097 million compared to ILS 52.074 million a year ago. Financial income was ILS 7.735 million compared to ILS 2.484 million a year ago. Comprehensive loss for the period was ILS 24.028 million compared to ILS 46.074 million a year ago. Basic and diluted loss per share were ILS 0.076 compared to ILS 0.209 a year ago. Net cash used in operating activities was ILS 38.335 million compared to ILS 55.911 million a year ago. The decrease in net cash used in operating activities was primarily the result of decreased research and development spending. Additions to property and equipment were ILS 0.545 million compared to ILS 0.196 million a year ago. Additions to intangible assets were ILS 0.010 million compared to ILS 0.096 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLRX:IT 67.00 +1.20

BLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation BLRX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLINERX LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at